Targets › IL17RA
2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 4; Immunology, Oncology, Other; next expected readout Jun 2027.
Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric…. (UniProt, Q96F46)
Open in Phaseline: the race on IL17RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bausch Health Americas | Brodalumab Interleukin-17 receptor A antagonist | IL17RA | Phase 4 | Psoriasis; Breast Cancer | Dec 2028 |
| Samsung Bioepis | SB35 IL-17A receptor antagonist | IL17RA | Phase 1 | Healthy | Jun 2027 |
Psoriasis (1) Breast Cancer (1) Healthy (1)
antibody (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.